BDX’s Non-GAAP Playbook: EU Regulation Costs, a Quiet Upgrade to the Underlying Picture

Ticker: BDX. In a filing that doubles as a reminder that the line between GAAP and “management’s view” still matters, Becton Dickinson and Company lays out its Condensed Consolidated Income Statements (Unaudited; Amounts in millions, except share and per share data) as Exhibit 99.1. The headline is not a dramatic earnings surprise or a revenue forecast shock; it’s a careful delineation of non-GAAP adjustments tied to European regulatory initiatives and a menu of other items BD says are outside its core, ongoing operations. The message for investors? Non-GAAP figures can illuminate the underlying rhythm of the business, but you should still measure them against reconciliations and the GAAP baseline. In other words, EPS and revenue would look different depending on whether you’re listening to the management drum solo or the GAAP orchestra.

What the filing covers

The document emphasizes non-GAAP measures that adjust the historical results by excluding a bundle of items: integration, restructuring, and transaction costs; financing impacts; separation-related items; certain regulatory costs; certain product, litigation, and other items; and the income tax benefit of these items. The standout example is European regulatory initiative-related costs, connected to establishing initial compliance with the European Union Medical Device Regulation and the European Union In Vitro Diagnostic Medical Device Regulation (the “New EU Medical Devices Regulations”). These costs are described as duplicative of previously incurred or one-off in nature and are limited to a specific period.

What’s more, BD explains where these costs show up in the income statement. They were primarily recorded in Cost of products sold and Research and development expense, covering labor, services and consulting (including R&D and clinical trials), as well as supplies, travel and other miscellaneous costs. The overall aim, BD says, is to aid investors in understanding the company’s performance year over year and to analyze underlying trends in its businesses.

Management’s stance—and the cautions that come with it

BD’s leadership argues that non-GAAP results help investors gauge what BD management considers its ongoing operative performance, especially when comparing to prior periods or forecasts. Yet the company also cautions that these non-GAAP measures can differ materially from GAAP results and may not be directly comparable to measures used by other companies, even if the same terminology is used. Reconciliations of these non-GAAP measures to GAAP figures are included in the attached financial tables, and you should expect rounding in the tables to produce minor arithmetic quirks.

The document’s framing mirrors a broader industry practice: carve out regulatory and one-off costs so the “normal” operating machine looks smoother. The risk, of course, is that a persistent or expanding set of regulatory costs could become a recurring headwind, potentially shifting the narrative from “clean, underlying growth” to “cost-burdened margins” over time.

What this might portend for BD and its sector peers

From a BD-centric lens, the inclusion of New EU Medical Devices Regulations costs as a non-GAAP adjustment underscores a few realities. First, regulatory compliance in the European market remains a meaningful, multi-year tailwind/tailwind hazard depending on policy clarity and implementation pace. Second, the non-GAAP presentation can temporarily flatter near-term EPS by excluding costs that management deems non-operational or one-off. Third, the company’s insistence on providing reconciliations reinforces a baseline commitment to transparency, even as the “adjusted” numbers invite closer scrutiny against GAAP results and consensus estimates.

For sector peers, the message is instructive: regulatory regimes are not a one-off expense but a structural feature of modern medical technology and diagnostic devices markets. If EU MDR/IVDR-like requirements remain front-and-center, expect more disclosures of regulatory costs stripped out of non-GAAP figures, with investors weighing the sustainability of those costs against growth drivers like product launches, market expansion, and cost-of-goods optimization. In this environment, the EPS consensus for medtech players could diverge between GAAP and adjusted views, and revenue forecasts might hinge on how effectively companies can commercialize new devices while absorbing regulatory expenditures.

In short, BD’s move is less about a single quarter’s fireworks and more about signaling how the company wants to frame its profitability trajectory in an increasingly regulated landscape. If you’re tracking the earnings surprise metric, the hurdle will be twofold: the GAAP narrative versus the non-GAAP one, and how each aligns with the revenue forecast the market has already priced in. Until the reconciliations land and analysts model the delta between core operating earnings and the regulatory drag, expect the conversation to orbit around margins, not just the headline top line.

Key takeaways

BDX presents non-GAAP measures that exclude European regulatory costs tied to the New EU Medical Devices Regulations, plus a broader set of items the company deems non-operational.
The European costs are described as initial-compliance efforts and are partially recorded in Cost of products sold and in Research and development expense.
Reconciliations to GAAP are provided in the attached financial tables; analysts should compare GAAP and non-GAAP figures to gauge the true momentum and the scale of the regulatory drag.
Investors should monitor EPS and EPS consensus in light of these adjustments, along with revenue forecasts, to judge whether BD’s non-GAAP picture aligns with the GAAP reality and market expectations.
Regulatory costs are likely to be a common theme across medtech peers, influencing both margins and strategic planning around R&D and international expansion.

Closing thought

BD’s Exhibit 99.1 is a reminder that the story of a modern industrial biotech business isn’t only about what the top line or the bottom line says today. It’s about the quality and nature of the costs that hover in the background—the kind that make an “earnings surprise” either more plausible or more elusive, depending on how you slice the numbers. In a market where EPS consensus and revenue forecast shifts carry weight, BD’s careful delineation of non-GAAP adjustments feels like a sensible reminder: if you want the true picture, read the footnotes and the reconciliations with the same tempo you’d allocate to a clinical trial protocol—details matter, and they’re rarely optional.